<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id><journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id><journal-title-group><journal-title>Frontiers in Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1664-0640</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26793128</article-id><article-id pub-id-type="pmc">4709416</article-id><article-id pub-id-type="doi">10.3389/fpsyt.2015.00186</article-id><article-categories><subj-group subj-group-type="heading"><subject>Psychiatry</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Cognitive Enhancement Therapy Improves Frontolimbic Regulation of Emotion in Alcohol and/or Cannabis Misusing Schizophrenia: A Preliminary Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wojtalik</surname><given-names>Jessica A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/113038"/></contrib><contrib contrib-type="author"><name><surname>Hogarty</surname><given-names>Susan S.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cornelius</surname><given-names>Jack R.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/171054"/></contrib><contrib contrib-type="author"><name><surname>Phillips</surname><given-names>Mary L.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/6523"/></contrib><contrib contrib-type="author"><name><surname>Keshavan</surname><given-names>Matcheri S.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/5901"/></contrib><contrib contrib-type="author"><name><surname>Newhill</surname><given-names>Christina E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eack</surname><given-names>Shaun M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>School of Social Work, University of Pittsburgh</institution>, <addr-line>Pittsburgh, PA</addr-line>, <country>USA</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Psychiatry, School of Medicine, University of Pittsburgh</institution>, <addr-line>Pittsburgh, PA</addr-line>, <country>USA</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Psychiatry, Harvard Medical School</institution>, <addr-line>Boston, MA</addr-line>, <country>USA</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Stefan Borgwardt, University of Basel, Switzerland</p></fn><fn fn-type="edited-by"><p>Reviewed by: Matthias Kirschner, Zurich University Hospital for Psychiatry, Switzerland; Marc Vogel, Psychiatric University Clinics Basel, Switzerland</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Jessica A. Wojtalik, <email>jew103@pitt.edu</email></corresp><fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Neuroimaging and Stimulation, a section of the journal Frontiers in Psychiatry</p></fn></author-notes><pub-date pub-type="epub"><day>12</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>6</volume><elocation-id>186</elocation-id><history><date date-type="received"><day>23</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Wojtalik, Hogarty, Cornelius, Phillips, Keshavan, Newhill and Eack.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Wojtalik, Hogarty, Cornelius, Phillips, Keshavan, Newhill and Eack</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Individuals with schizophrenia who misuse substances are burdened with impairments in emotion regulation. Cognitive enhancement therapy (CET) may address these problems by enhancing prefrontal brain function. A small sample of outpatients with schizophrenia and alcohol and/or cannabis substance use problems participating in an 18-month randomized trial of CET (<italic>n</italic>&#x02009;=&#x02009;10) or usual care (<italic>n</italic>&#x02009;=&#x02009;4) completed posttreatment functional neuroimaging using an emotion regulation task. General linear models explored CET effects on brain activity in emotional neurocircuitry. Individuals treated with CET had significantly greater activation in broad regions of the prefrontal cortex, limbic, and striatal systems implicated in emotion regulation compared to usual care. Differential activation favoring CET in prefrontal regions and the insula mediated behavioral improvements in emotional processing. Our data lend preliminary support of CET effects on neuroplasticity in frontolimbic and striatal circuitries, which mediate emotion regulation in people with schizophrenia and comorbid substance misuse problems.</p></abstract><kwd-group><kwd>schizophrenia</kwd><kwd>alcohol misuse</kwd><kwd>cannabis misuse</kwd><kwd>emotion regulation</kwd><kwd>brain</kwd><kwd>cognitive enhancement therapy</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source><award-id rid="cn01">DA-30763, MH-95783, RR-24154</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><equation-count count="0"/><ref-count count="71"/><page-count count="11"/><word-count count="8050"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Substance misuse among individuals with schizophrenia is substantially higher compared to the general population (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>), which has been linked to problems in emotion dysregulation (<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>), defined as the inability to tolerate and appropriately manage emotions, particularly negative affects. Individuals with schizophrenia who misuse substances tend to function worse in the community (<xref rid="B6" ref-type="bibr">6</xref>), experience lower quality of life (<xref rid="B7" ref-type="bibr">7</xref>), treatment non-adherence (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>), and have higher rates of relapse often leading to emergency room contact and/or hospitalization (<xref rid="B10" ref-type="bibr">10</xref>). Indeed, the experience of overall greater severity of the illness in this population often results in two to three times more hospitalizations than patients with schizophrenia who do not abuse substances (<xref rid="B11" ref-type="bibr">11</xref>). Misuse of substances has been proposed to exacerbate symptoms (<xref rid="B12" ref-type="bibr">12</xref>), such that positive symptoms tend to be particularly more severe in people with schizophrenia and comorbid substance misuse diagnoses (<xref rid="B13" ref-type="bibr">13</xref>). Cannabis and alcohol have been indicated to be the two most commonly misused substances among individuals with schizophrenia (<xref rid="B2" ref-type="bibr">2</xref>). While literature on the relationship between substance misuse and cognitive functioning in schizophrenia have been mixed and difficult to interpret (<xref rid="B14" ref-type="bibr">14</xref>), generally it can be inferred that individuals with schizophrenia who misuse alcohol or cannabis experience cognitive deficits (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). In a recent randomized-controlled trial, we found that cognitive enhancement therapy [CET (<xref rid="B17" ref-type="bibr">17</xref>)] resulted in significant improvements in emotion regulation abilities among people with schizophrenia and alcohol and/or cannabis use problems, as well as significant reductions in alcohol use (<xref rid="B18" ref-type="bibr">18</xref>). CET is a psychosocial cognitive remediation intervention (<xref rid="B19" ref-type="bibr">19</xref>) that integrates 60&#x02009;h of computer-based training targeted at improving attention, memory, and problem solving with 45 structured social-cognitive group sessions designed to improve abilities, such as perspective taking, social context appraisal, and emotion regulation abilities. Examination of the neurobiological underpinnings of improved emotion regulation associated with cognitive remediation can yield important information about the plasticity of neural mechanisms that can support addiction and psychiatric recovery in this population.</p><p>The affect regulation model has been one of the most empirically supported conceptualizations of the nature of high rates of substance misuse among individuals with schizophrenia (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B5" ref-type="bibr">5</xref>). This model proposes that individuals with schizophrenia who are high in trait negative affect are more likely to misuse substances as a way to cope and regulate the intensity of negative emotional states (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). In support of this model, numerous studies have found that people with schizophrenia report that they misuse substances to relieve or buffer dysregulated negative emotions (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). The brain circuitry for supporting successful emotion regulation involves regions in the prefrontal cortex, limbic system, and the striatum (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B24" ref-type="bibr">24</xref>), which are also regions thought to be impacted by the pharmacological effects of addiction (<xref rid="B25" ref-type="bibr">25</xref>) and the symptoms of schizophrenia (<xref rid="B26" ref-type="bibr">26</xref>). For example, dysfunctional communication between the nucleus accumbens, frontal cortex, and hippocampus observed in non-substance abusing schizophrenia patients is similar to the substance abuse-related neurobiological changes observed in primary additive disorders (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>Based on the aforementioned findings, we posit that participation in cognitive remediation interventions may alter functioning of the frontal, limbic, and striatal neurocircuitry to support improvement in emotion regulation in individuals with schizophrenia and substance misuse comorbidity. Meta-analytic evidence is supportive of neuroplasticity or &#x0201c;brain changing&#x0201d; effects of cognitive remediation interventions, where individuals with schizophrenia have demonstrated increased brain function in prefrontal, limbic, and striatal regions following treatment (<xref rid="B27" ref-type="bibr">27</xref>). Additionally, protection against gray matter loss in limbic regions has been observed in early course schizophrenia outpatients treated with CET (<xref rid="B28" ref-type="bibr">28</xref>). Both increased neural activation and gray matter in frontolimbic and striatal regions were associated with improved cognitive and socioemotional outcomes (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Although substance misuse is often an exclusion criterion in cognitive remediation trials (<xref rid="B29" ref-type="bibr">29</xref>), such findings suggest that these treatments, such as CET, may have the ability to strengthen neurobiological functions that govern emotional circuitry in individuals with schizophrenia and substance misuse comorbidity (<xref rid="B29" ref-type="bibr">29</xref>). However, no study has examined the neurobiological effects of cognitive remediation in people with schizophrenia who misuse substances.</p><p>Identifying biomarkers of therapeutic mechanisms in the treatment of individuals with schizophrenia is imperative for the continued understanding of the pathophysiology of the illness and the impact of substance misuse. More importantly, understanding the neurobiological effects of cognitive remediation could reinforce the utility of such interventions (<xref rid="B19" ref-type="bibr">19</xref>) to intervene with the diversity of challenges people with schizophrenia face, including substance misuse. Therefore, this preliminary study sought to explore the posttreatment neurobiological impact of CET on frontolimbic and striatal brain functioning during the effortful regulation of emotion in a small sample of individuals with schizophrenia who misuse alcohol and/or cannabis, the two most commonly abused substances in this population (<xref rid="B2" ref-type="bibr">2</xref>). The degree to which posttreatment brain functioning during emotion regulation was related to longitudinal behavioral improvements in emotion processing was also investigated.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S2-1"><title>Participants</title><p>A total of 14 individuals diagnosed with schizophrenia (<italic>n</italic>&#x02009;=&#x02009;10) or schizoaffective disorder (<italic>n</italic>&#x02009;=&#x02009;4) and alcohol and/or cannabis misuse problems were included in an 18-month randomized feasibility study (NCT01292577) of CET compared to treatment as usual [TAU (<xref rid="B18" ref-type="bibr">18</xref>)]. All participants provided written informed consent prior to their participation. The study protocol was approved by the University of Pittsburgh Institutional Review Board, was reviewed annually, and was registered in the national clinical trials database. There were 31 participants included in the larger randomized feasibility trial of CET (<xref rid="B18" ref-type="bibr">18</xref>), with 14 subjects (<italic>n</italic>&#x02009;=&#x02009;10 CET and <italic>n</italic>&#x02009;=&#x02009;4 TAU) available for functional magnetic resonance imaging (fMRI) after completing treatment. The reasons for participants being unavailable for scanning included withdrawing consent (<italic>n</italic>&#x02009;=&#x02009;5), incarceration (<italic>n</italic>&#x02009;=&#x02009;1), cocaine abuse (<italic>n</italic>&#x02009;=&#x02009;1), symptom instability (<italic>n</italic>&#x02009;=&#x02009;4), heroin dependence (<italic>n</italic>&#x02009;=&#x02009;1), lack of interest in being scanned (<italic>n</italic>&#x02009;=&#x02009;2), unable to contact (<italic>n</italic>&#x02009;=&#x02009;2), and ferromagnetic objects in the body (<italic>n</italic>&#x02009;=&#x02009;1). Inclusion criteria for the participants were (1) age between 18 and 60, (2) diagnosis of schizophrenia or schizoaffective disorder based on the Structured Clinical Interview for the DSM-IV [SCID (<xref rid="B30" ref-type="bibr">30</xref>)], (3) presentation of significant cognitive and social disability on the Cognitive Styles and Social Cognition Eligibility Interview (<xref rid="B31" ref-type="bibr">31</xref>), (4) an Addiction Severity Index (<xref rid="B32" ref-type="bibr">32</xref>) score of moderate or higher (&#x02265;4) addiction severity for cannabis or alcohol use, (5) stabilization on antipsychotic medications, (6) an IQ&#x02009;&#x02265;&#x02009;80, (7) the ability to speak and read fluent English, (8) no current cocaine, amphetamine, or opioid abuse or dependence, (9) not receiving substance abuse pharmacotherapies (e.g., naltrexone), (10) no significant cognitive impairment caused by the presence of a persistent medical condition, (11) no persistent suicidal or homicidal behavior, and (12) free of any MRI contraindications.</p><p>See Table <xref ref-type="table" rid="T1">1</xref> for a full description of participant characteristics. Overall, participants with fMRI data had an average age of 38.71 (SD&#x02009;=&#x02009;13.26) years, were ill for an average duration of 14.93 (SD&#x02009;=&#x02009;10.38) years, and completed 14.50 (SD&#x02009;=&#x02009;1.61) years of education. Eighty-six percent (<italic>n</italic>&#x02009;=&#x02009;12) of the participants also had a comorbid alcohol and/or cannabis misuse diagnosis based on the SCID (<xref rid="B30" ref-type="bibr">30</xref>). Two participants did not meet SCID criteria for a comorbid alcohol and/or cannabis misuse diagnosis, but met for the inclusion criteria of an Addiction Severity Index (<xref rid="B32" ref-type="bibr">32</xref>) score of moderate or higher (&#x02265;4) addiction severity for cannabis or alcohol use. The participants were ethnically diverse (seven Caucasian, six African American, and one Asian) and a little more than half were male (<italic>n</italic>&#x02009;=&#x02009;8, 57%). Although the majority of the participants had some college education (<italic>n</italic>&#x02009;=&#x02009;11, 79%) and most were not employed (<italic>n</italic>&#x02009;=&#x02009;11, 79%) at the time of baseline assessment. Participants randomized to either CET (<italic>n</italic>&#x02009;=&#x02009;10) or TAU (<italic>n</italic>&#x02009;=&#x02009;4) did not significantly differ with regard to the above demographic variables (all <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.271), baseline IQ (<italic>p</italic>&#x02009;=&#x02009;0.541), BPRS total score (<italic>p</italic>&#x02009;=&#x02009;0.258), antipsychotic medication dose (<italic>p</italic>&#x02009;=&#x02009;0.464), type of antipsychotic mediation (0.505), or adherence to antipsychotic medication (<italic>p</italic>&#x02009;=&#x02009;1.00). The observation of a non-significant difference between CET and TAU participants with regard to type of antipsychotic medication is important given that typical and atypical antipsychotics may impact brain functioning differently (<xref rid="B33" ref-type="bibr">33</xref>). The CET participants were non-significantly older than the TAU participants, and there were more Caucasian participants in the CET group (<italic>n</italic>&#x02009;=&#x02009;6, 60%) compared to only one (25%) Caucasian participant in the TAU group. Consequently, age and race were included as confounding covariates in all analyses of the differential effects of CET compared to TAU on brain function.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Baseline characteristics of CET and TAU participants with schizophrenia who misuse alcohol and/or cannabis presented as <italic>N</italic> (%) or <italic>M</italic> (SD)</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="left" rowspan="1" colspan="1">Total (<italic>n</italic>&#x02009;<bold>=</bold>&#x02009;14)</th><th valign="top" align="left" rowspan="1" colspan="1">CET (<italic>n</italic>&#x02009;<bold>=</bold>&#x02009;10)</th><th valign="top" align="left" rowspan="1" colspan="1">TAU (<italic>n</italic>&#x02009;<bold>=</bold>&#x02009;4)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="top" rowspan="1" colspan="1">38.7 (13.26)</td><td align="left" valign="top" rowspan="1" colspan="1">41.20 (13.65)</td><td align="left" valign="top" rowspan="1" colspan="1">32.50 (11.45)</td><td align="left" valign="top" rowspan="1" colspan="1">0.285</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (male)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (57%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (60%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race: Caucasian</td><td align="left" valign="top" rowspan="1" colspan="1">7 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (60%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (25%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;African-American</td><td align="left" valign="top" rowspan="1" colspan="1">6 (43%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (40%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (50%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.271</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;Asian</td><td align="left" valign="top" rowspan="1" colspan="1">1 (7%)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">1 (25%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IQ</td><td align="left" valign="top" rowspan="1" colspan="1">101.43 (11.69)</td><td align="left" valign="top" rowspan="1" colspan="1">102.70 (13.6)</td><td align="left" valign="top" rowspan="1" colspan="1">98.25 (4.27)</td><td align="left" valign="top" rowspan="1" colspan="1">0.541</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Attended college</td><td align="left" valign="top" rowspan="1" colspan="1">11 (79%)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (80%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (75%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Education (years)</td><td align="left" valign="top" rowspan="1" colspan="1">14.50 (1.61)</td><td align="left" valign="top" rowspan="1" colspan="1">14.6 (1.65)</td><td align="left" valign="top" rowspan="1" colspan="1">14.25 (1.71)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Not employed</td><td align="left" valign="top" rowspan="1" colspan="1">11 (79%)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (70%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.505</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Illness length (years)</td><td align="left" valign="top" rowspan="1" colspan="1">14.93 (10.38)</td><td align="left" valign="top" rowspan="1" colspan="1">15.50 (10.52)</td><td align="left" valign="top" rowspan="1" colspan="1">13.5 (11.45)</td><td align="left" valign="top" rowspan="1" colspan="1">0.759</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BPRS total</td><td align="left" valign="top" rowspan="1" colspan="1">42.93 (10.26)</td><td align="left" valign="top" rowspan="1" colspan="1">40.90 (7.77)</td><td align="left" valign="top" rowspan="1" colspan="1">48.0 (15.08)</td><td align="left" valign="top" rowspan="1" colspan="1">0.258</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ASI: alcohol</td><td align="left" valign="top" rowspan="1" colspan="1">4.5 (2.68)</td><td align="left" valign="top" rowspan="1" colspan="1">4.40 (3.10)</td><td align="left" valign="top" rowspan="1" colspan="1">4.75 (1.50)</td><td align="left" valign="top" rowspan="1" colspan="1">0.835</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ASI: drug</td><td align="left" valign="top" rowspan="1" colspan="1">3.14 (2.14)</td><td align="left" valign="top" rowspan="1" colspan="1">3.0 (2.49)</td><td align="left" valign="top" rowspan="1" colspan="1">3.50 (1.00)</td><td align="left" valign="top" rowspan="1" colspan="1">0.710</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1">Principle diagnosis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Schizophrenia</td><td align="left" valign="top" rowspan="1" colspan="1">10 (71%)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (80%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (50%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Schizoaffective</td><td align="left" valign="top" rowspan="1" colspan="1">4 (29%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (20%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (50%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.520</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Substance abuse or dependence diagnosis</td><td align="left" valign="middle" rowspan="1" colspan="1">12 (86%)</td><td align="left" valign="middle" rowspan="1" colspan="1">9 (90%)</td><td align="left" valign="middle" rowspan="1" colspan="1">3 (75%)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.505</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Alcohol dependence</td><td align="left" valign="top" rowspan="1" colspan="1">7 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Alcohol abuse</td><td align="left" valign="top" rowspan="1" colspan="1">2 (14%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (20%)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Cannabis dependence</td><td align="left" valign="top" rowspan="1" colspan="1">7 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (50%)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Cannabis abuse</td><td align="left" valign="top" rowspan="1" colspan="1">1 (7%)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">1 (25%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.286</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1">Daily substance use among active users</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Alcohol use occasions per day</td><td align="left" valign="top" rowspan="1" colspan="1">2.15 (2.39)</td><td align="left" valign="top" rowspan="1" colspan="1">2.59 (2.42)</td><td align="left" valign="top" rowspan="1" colspan="1">1.07 (2.14)</td><td align="left" valign="top" rowspan="1" colspan="1">0.301</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Cannabis use occasions per day</td><td align="left" valign="top" rowspan="1" colspan="1">0.34 (0.85)</td><td align="left" valign="top" rowspan="1" colspan="1">0.48 (0.98)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">0.363</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1">Antipsychotic medication</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Atypical</td><td align="left" valign="top" rowspan="1" colspan="1">11 (79%)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (70%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (100%)</td><td align="left" valign="middle" rowspan="2" colspan="1">0.505</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Typical</td><td align="left" valign="top" rowspan="1" colspan="1">3 (21%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (30%)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Dose (CPZ equivalent)</td><td align="left" valign="top" rowspan="1" colspan="1">449.52 (360.69)</td><td align="left" valign="top" rowspan="1" colspan="1">402.67 (370.68)</td><td align="left" valign="top" rowspan="1" colspan="1">566.67 (354.86)</td><td align="left" valign="top" rowspan="1" colspan="1">0.464</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Adherent</td><td align="left" valign="top" rowspan="1" colspan="1">13 (93%)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (90%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (100%)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1">MSCEIT total score</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">87.33 (14.98)</td><td align="left" valign="top" rowspan="1" colspan="1">85.94 (14.27)</td><td align="left" valign="top" rowspan="1" colspan="1">90.82 (18.40)</td><td align="left" valign="top" rowspan="1" colspan="1">0.602</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Posttreatment</td><td align="left" valign="top" rowspan="1" colspan="1">91.17 (15.53)</td><td align="left" valign="top" rowspan="1" colspan="1">92.19 (14.98)</td><td align="left" valign="top" rowspan="1" colspan="1">88.61 (18.96)</td><td align="left" valign="top" rowspan="1" colspan="1">0.713</td></tr><tr><td align="left" valign="top" colspan="5" rowspan="1">ER-40 correct response</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Baseline</td><td align="left" valign="top" rowspan="1" colspan="1">32.29 (3.45)</td><td align="left" valign="top" rowspan="1" colspan="1">31.90 (3.96)</td><td align="left" valign="top" rowspan="1" colspan="1">33.25 (1.71)</td><td align="left" valign="top" rowspan="1" colspan="1">0.530</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Posttreatment</td><td align="left" valign="top" rowspan="1" colspan="1">33.18 (3.05)</td><td align="left" valign="top" rowspan="1" colspan="1">33.35 (3.54)</td><td align="left" valign="top" rowspan="1" colspan="1">32.75 (1.50)</td><td align="left" valign="top" rowspan="1" colspan="1">0.754</td></tr></tbody></table><table-wrap-foot><p><italic>ASI, Addiction Severity Index; BPRS, Brief Psychiatric Rating Scale; CPZ, chlorpromazine, MSCEIT, The Mayer&#x02013;Salovey&#x02013;Caruso Emotional Intelligence Test; ER-40, Penn Emotion Recognition Test-40</italic>.</p><fn id="tfn1"><p><italic><sup>a</sup>Results from independent sample <italic>t</italic>-tests or Fisher&#x02019;s exact tests, two-tailed</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="S2-2"><title>Emotional Faces <italic>n</italic>-Back Task</title><p>Brain functioning during the effortful regulation of emotion was elicited using an emotional faces <italic>n</italic>-back task, which is a modified version of the standard working memory <italic>n</italic>-back task including 0-back and 2-back working memory conditions (<xref rid="B34" ref-type="bibr">34</xref>). An <italic>n</italic>-back task is one that asks participants to respond when they view a stimulus (e.g., letter) that is the same as that presented <italic>n</italic> trails previously. In addition to the working memory conditions (0-back and 2-back), four emotional valence distracter conditions (no faces, happy faces, fearful faces, and neutral faces) were presented to participants. Faces were flanked on each side of the <italic>n</italic>-back letter stimuli (Figure <xref ref-type="fig" rid="F1">1</xref>). The faces were from the NimStim dataset in grayscale (<xref rid="B35" ref-type="bibr">35</xref>), were normalized for size and luminance, and balanced by gender. Both working memory and emotional valence conditions were presented in randomized blocks of 12 trials each. By directing participants&#x02019; attention to the working memory components of the task, participants were required to inhibit their response to the emotional stimuli in order to successfully complete the <italic>n</italic>-back tasks (<xref rid="B36" ref-type="bibr">36</xref>), and thus this task is considered a test of effortful emotion regulation. Each block started with instructions indicating the working memory condition (0-back or 2-back) presented on the screen for 3500&#x02009;ms, which was followed by the target stimulus (letters) presented flanked by the different emotional valence distracter conditions (happy, fearful, neutral, or no face) for 500&#x02009;ms, with an interstimulus interval jittered at an average of 3500&#x02009;ms. The total task time was 6&#x02009;min and 56&#x02009;s with each emotional valence distracter condition presented once for both the 0-back and 2-back conditions. All the participants completed two runs of the emotional faces <italic>n</italic>-back paradigm, with the exception of one TAU participant that completed one run. Since the focus of this research was on emotion regulation during effortful cognitive processing, only data from the effortful 2-back condition were analyzed.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Example of a 2-back happy face distracter condition from the emotional faces <italic>n</italic>-back task</bold>. [Reproduced with permission from Ladouceur et al. (<xref rid="B34" ref-type="bibr">34</xref>)].</p></caption><graphic xlink:href="fpsyt-06-00186-g001"/></fig></sec><sec id="S2-3"><title>Image Acquisition and Processing</title><p>A 3-T Siemens Verio whole-body scanner with a 12-channel head coil was used to collect structural and functional neuroimaging data at the Scientific Imaging and Brain Research Center at Carnegie Mellon University. Functional MRI data were acquired using an echo T2*-weighted sequence with real-time motion correction (3.2&#x02009;mm&#x02009;&#x000d7;&#x02009;3.2&#x02009;mm&#x02009;&#x000d7;&#x02009;3.2&#x02009;mm voxel size, TR&#x02009;=&#x02009;2000&#x02009;ms, TE&#x02009;=&#x02009;30&#x02009;ms, bandwidth&#x02009;=&#x02009;2298&#x02009;Hz/px, FOV&#x02009;=&#x02009;205&#x02009;mm, flip angle&#x02009;=&#x02009;79&#x000b0;, 64&#x02009;&#x000d7;&#x02009;64 matrix, 36 slices, slice thickness&#x02009;=&#x02009;3.2&#x02009;mm).</p><p>Statistical Parametric Mapping Software, version 8 (SPM8; Wellcome Department of Cognitive Neurology, Institute of Neurology, London, UK) was used to preprocess imaging data. The images were normalized to a common Montreal Neurological Institute (MNI) coordinate space using an indirect normalization pipeline, with parameters obtained from a high-resolution T1 structural image. Images were smoothed with an 8-mm full-width at half maximum Gaussian kernel. Signal and movement outliers were identified using the Artifact Detection Tool (<xref rid="B37" ref-type="bibr">37</xref>) software package and entered into each participant&#x02019;s first-level general linear model as regressors of no interest.</p></sec><sec id="S2-4"><title>Emotion Processing Behavioral Measures</title><p>In addition to assessing brain functioning during effortful emotion regulation measured by the emotional faces <italic>n</italic>-back task outlined above, behavioral measures of emotion processing were also utilized in the parent study (<xref rid="B18" ref-type="bibr">18</xref>) to examine behavioral emotion processing skills at pre- and posttreatment. The Mayer&#x02013;Salovey&#x02013;Caruso Emotional Intelligence Test [MSCEIT (<xref rid="B38" ref-type="bibr">38</xref>)] and the Penn Emotion Recognition Test-40 [ER-40 (<xref rid="B39" ref-type="bibr">39</xref>)] were the measures used to assess emotion processing. Noteworthy, brain regions important for emotion processing, which includes emotion regulation, such as limbic areas, have been shown to be associated with performance on both these measures (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>).</p><p>The MSCEIT is a 141-item performance-based measure of emotion processing and management (e.g., emotional intelligence) that is administered on the computer (<xref rid="B42" ref-type="bibr">42</xref>). Performance scores are based on a large normative sample scale (<italic>M</italic>&#x02009;=&#x02009;100, SD&#x02009;=&#x02009;15), with a higher score indicating a better emotional intelligence quotient (<xref rid="B38" ref-type="bibr">38</xref>). The MSCEIT is a recommended measure of the National Institute of Mental Health&#x02019;s committee on Measurement and Treatment Research to Improve Cognition in Schizophrenia [NIMH-MATRICS (<xref rid="B43" ref-type="bibr">43</xref>)] and has been shown to have good reliability and sufficient construct and concurrent validity (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). The ER-40 is also a frequently utilized measure of emotion processing in schizophrenia, as it has good psychometric properties (<xref rid="B45" ref-type="bibr">45</xref>) and is able to discriminate between healthy controls and individuals with schizophrenia (<xref rid="B39" ref-type="bibr">39</xref>). The ER-40 is a forced-choice, computer-administered assessment of the ability to accurately recognize different emotions. The task involves a series of 40 happy, sad, angry, fearful, or neutral (non-emotional) faces. Scores represent number of correct responses, with a higher score indicating better performance.</p></sec></sec><sec id="S3"><title>Treatments</title><sec id="S3-1"><title>Medication</title><p>All participants were maintained on antipsychotic medications approved for the treatment of schizophrenia or schizoaffective disorder as prescribed by their treating psychiatrist. Table <xref ref-type="table" rid="T1">1</xref> lists antipsychotic medication characteristics of the participants.</p></sec><sec id="S3-2"><title>Cognitive Enhancement Therapy</title><p>Cognitive enhancement therapy is a performance-based, comprehensive, developmental approach to the remediation of social-cognitive and neurocognitive deficits in participants with schizophrenia (<xref rid="B17" ref-type="bibr">17</xref>). CET consists of 60&#x02009;h of weekly computer-based neurocognitive training to in attention, memory and problem-solving and 45 small-group sessions to address social-cognitive deficits that limit functional recovery from schizophrenia. To encourage socialization, neurocognitive training is implemented in patient pairs and conducted with coaching from a CET therapist. One-hour neurocognitive training sessions begin with Ben-Yishay&#x02019;s Orientation Remediation Module (<xref rid="B46" ref-type="bibr">46</xref>) to improve different aspects of attention and speed of processing. Following ~3&#x02009;months of attention training, 3&#x02013;4 participants combine to form a social-cognitive group. The 1.5-h social-cognitive group sessions utilize experiential learning approaches to teach a wide range of social-cognitive abilities designed to enhance social wisdom and interpersonal success. Key theoretically driven components of the social-cognitive groups include perspective-taking, social gist abstraction, non-verbal communication, emotion management, and foresightfulness. The social-cognitive group curriculum encourages participants to engage in activities that include responding to unrehearsed social exchanges, presenting homework, participating in social-cognitive exercises, providing feedback to others, and leading homework review. Neurocognitive training in memory and problem-solving using PSSCogReHab (<xref rid="B47" ref-type="bibr">47</xref>) software proceeds concurrently with the social-cognitive groups after the conclusion of attention training. A complete description of CET has been provided elsewhere (<xref rid="B17" ref-type="bibr">17</xref>).</p></sec><sec id="S3-3"><title>Treatment As Usual</title><p>Treatment as usual served as the comparison treatment condition in this randomized feasibility trial of CET for schizophrenia participants who misuse substances. TAU consisted of traditional social services and mental health programs, which included psychiatric services, case management, individual supportive therapy, vocational rehabilitation, dual diagnosis treatment programs, and other community-based treatments for substance use. All efforts were made to link both CET and TAU participants with necessary mental health and substance abuse services while participating in the study.</p></sec></sec><sec id="S4"><title>Procedures</title><p>Participants were recruited from Western Psychiatric Institute and Clinic and other community clinics at Pittsburgh, PA, USA. Potential participants were screened for eligibility using the SCID (<xref rid="B30" ref-type="bibr">30</xref>), the Ammons Quick IQ Test (<xref rid="B48" ref-type="bibr">48</xref>), the Addiction Severity Index (<xref rid="B32" ref-type="bibr">32</xref>), and the Cognitive Style and Social Cognition Eligibility Interview (<xref rid="B31" ref-type="bibr">31</xref>). Those participants meeting inclusion criteria were then randomized to receive 18&#x02009;months of either CET or TAU. Individuals were then assessed every 6&#x02009;months using the aforementioned behavioral emotion processing measures. A subset of 14 participants (<italic>n</italic>&#x02009;=&#x02009;10 CET, <italic>n</italic>&#x02009;=&#x02009;4 TAU) completed posttreatment fMRI scanning. Neuroimaging assessments were only available posttreatment as part of a separate pilot study that became available near the end of the larger feasibility trial of CET for alcohol and/or cannabis misusing schizophrenia (<xref rid="B18" ref-type="bibr">18</xref>). See Eack et al. (<xref rid="B18" ref-type="bibr">18</xref>) for details on this larger feasibility trial, such as the randomization procedures and the enrollment diagram. All participants provided written informed consent prior to their participation. The study protocol was approved by the University of Pittsburgh Institutional Review Board, was reviewed annually, and was registered in the national clinical trials database (NCT01292577).</p><sec id="S4-1"><title>Data Analysis</title><p>Functional neuroimaging data are inherently hierarchical in nature, with brain images (collected every 2&#x02009;s) nested within individuals in a time series. Analysis proceeds by first estimating the effects of task condition on brain activity for each individual (first-level analysis) and then subjecting those contrasts to group (second-level) analyses (<xref rid="B49" ref-type="bibr">49</xref>). SPM8 was utilized for first- and second-level voxel-based analyses to examine the differential posttreatment effects of CET compared to TAU on emotion regulation-related brain functioning. First-level analyses consisted of modeling neural responses during each condition of the emotional faces <italic>n</italic>-back task with general linear models in each of the participants. First-level models also included the signal and motion outliers identified by the Artifact Detection Tool as covariates (<xref rid="B37" ref-type="bibr">37</xref>). First-level contrasts (happy face vs. no face, fearful face vs. no face, and neutral face vs. no face) were then entered into a second-level group analysis based on a two (CET vs. TAU)&#x02009;&#x000d7;&#x02009;three (happy face vs. no face, fearful face vs. no face, and neutral face vs. no face) general linear model. To control the effect of general visual stimulation, the second-level contrasts compared emotional faces to neutral faces [e.g., (happy vs. no face)&#x02013;(neutral vs. no face)]. As mentioned above, second-level models included age and race as confounding covariates. A single region of interest mask was created in the Wake Forest University PickAtlas toolbox (<xref rid="B50" ref-type="bibr">50</xref>) with anatomical definitions provided by Tzourio-Mazoyer, Landeau (<xref rid="B51" ref-type="bibr">51</xref>). Regions of interest included frontolimbic and striatal areas, which were the bilateral amygdala, insula, dorsolateral prefrontal cortex (DLPFC), ventromedial prefrontal cortex, orbitofrontal cortex, striatum, nucleus accumbens, and the anterior cingulate cortex. These regions have been repeatedly implicated in the regulation of emotion (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B52" ref-type="bibr">52</xref>). Due to the conservativeness of voxel-wise multiple comparison corrections in small samples (<xref rid="B53" ref-type="bibr">53</xref>), Type I error was controlled using a cluster-extent thresholding method. Cluster-level correction with a small sample may provide the best balance between type I and type II error (<xref rid="B54" ref-type="bibr">54</xref>). Based on 10,000 Monte Carlo simulations executed in 3dClustSim (<xref rid="B55" ref-type="bibr">55</xref>), type I error was indicated to be controlled at an &#x003b1;-level of 0.05 using a combined threshold of a voxel extent of 34 and an uncorrected <italic>p</italic> of 0.001.</p><p>Associations between differential posttreatment effects during emotion regulation-related brain functioning and changes in behavioral emotion regulation performance from pre- to posttreatment were analyzed with bivariate correlations and mediator models executed in R 3.1.2 (<xref rid="B56" ref-type="bibr">56</xref>). It was determined that age, race, and antipsychotic medication dose were not significantly related to emotion processing behavioral performance and emotion regulation-related brain functioning. Therefore, these variables were not included as covariates to retain statistical power in correlations and mediator models. Average magnitude estimates per region of interest per participant were extracted using MarsBar, version 0.44 [<uri xlink:type="simple" xlink:href="http://marsbar.sourceforge.net">http://marsbar.sourceforge.net</uri> (<xref rid="B57" ref-type="bibr">57</xref>)] from the above imaging analysis to be utilized for correlation and mediation analyses. A path analysis approach was used for the mediation analysis (<xref rid="B58" ref-type="bibr">58</xref>), which was based on the mediator-analytic framework presented by Kraemer et al. (<xref rid="B59" ref-type="bibr">59</xref>) for randomized clinical trials. Mediator models were constructed with a series of linear models (<xref rid="B60" ref-type="bibr">60</xref>) that analyzed the indirect effects of treatment assignment (predictor) on longitudinal changes in emotion processing behavioral performance (outcome) through posttreatment emotion regulation-related brain functioning (mediator). This was accomplished by computing the association between (1) treatment assignment and emotion regulation-related brain functioning, (2) emotion regulation-related brain function and longitudinal changes in emotion processing behavioral performance, and (3) treatment assignment and longitudinal changes in emotion processing behavioral performance. Based on MacKinnon et al. (<xref rid="B61" ref-type="bibr">61</xref>), the magnitude and significance of the mediation effects was estimated using an asymptotic <italic>z</italic>&#x02032; test of indirect effects. Logarithmic transformations were used to correct any variables with significantly skewed distributions prior to analysis, which included the left inferior orbital frontal cortex, right DLPFC (BA 46), and reaction time from the emotional faces <italic>n</italic>-back. Missing data were handled with an expectation-maximization approach (<xref rid="B62" ref-type="bibr">62</xref>).</p></sec></sec><sec id="S5"><title>Results</title><sec id="S5-1"><title>Emotional Faces <italic>n</italic>-Back Task Performance</title><p>Reaction time and accuracy performance on the emotional faces <italic>n</italic>-back task was also analyzed in R with mixed-effects models examining group (CET vs. TAU), working memory loading (0-back vs. 2-back) and emotional distracter valence (happy vs. fearful vs. neutral vs. no faces) effects. One TAU participant had accuracy data available but did not have recorded reaction time data due to technical issues. Investigation of task performance on the emotional faces <italic>n</italic>-back task during scanning revealed that participants had neither overall high accuracy, with no significant group (<italic>p</italic>&#x02009;=&#x02009;0.228) or emotional distracter valence differences (<italic>p</italic>&#x02009;=&#x02009;0.803) nor were there any significant group by emotional distracter valence interactions (<italic>p</italic>&#x02009;=&#x02009;0.921), group by working memory loading interactions (<italic>p</italic>&#x02009;=&#x02009;0.369), or group by emotional distracter valence by working memory loading interactions (<italic>p</italic>&#x02009;=&#x02009;0.918). Accuracy was high across both groups of participants, however, significantly lower for the 2-back condition (93%) compared to the 0-back condition (97%), <italic><italic>&#x003c7;</italic></italic><sup>2</sup> (1, <italic>N</italic>&#x02009;=&#x02009;14)&#x02009;=&#x02009;9.68, <italic>p</italic>&#x02009;=&#x02009;0.002.</p><p>Overall, participants did not significantly differ in reaction times with regard to group assignment (<italic>p</italic>&#x02009;=&#x02009;0.695). With regard to the working memory loading condition, the participants had significantly slower reaction times during the 2-back condition (<italic>M</italic>&#x02009;=&#x02009;6.73 ms<sub>log</sub>, SE&#x02009;=&#x02009;0.06) compared to the 0-back condition (<italic>M</italic>&#x02009;=&#x02009;6.44 ms<sub>log</sub>, SE&#x02009;=&#x02009;0.06), <italic><italic>&#x003c7;</italic></italic><sup>2</sup> (1, <italic>N</italic>&#x02009;=&#x02009;13)&#x02009;=&#x02009;72.81, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. CET and TAU participants had similar reaction times during the 0-back (CET: <italic>M</italic>&#x02009;=&#x02009;6.44 ms<sub>log</sub>, SE&#x02009;=&#x02009;0.05; TAU: <italic>M</italic>&#x02009;=&#x02009;6.42 ms<sub>log</sub>, SE&#x02009;=&#x02009;0.10), but during the 2-back condition, the CET participants had significantly slower reaction times (<italic>M</italic>&#x02009;=&#x02009;6.78 ms<sub>log</sub>, SE&#x02009;=&#x02009;0.05) compared to the TAU participants (<italic>M</italic>&#x02009;=&#x02009;6.68 ms<sub>log</sub>, SE&#x02009;=&#x02009;0.10), <italic><italic>&#x003c7;</italic></italic><sup>2</sup> (1, <italic>N</italic>&#x02009;=&#x02009;13)&#x02009;=&#x02009;3.86, <italic>p</italic>&#x02009;=&#x02009;0.049. Participants did neither significantly differ in reaction times with regard to emotional valence distracters (<italic>p</italic>&#x02009;=&#x02009;0.058) nor were significant interactions observed for group by emotional distracter valence (<italic>p</italic>&#x02009;=&#x02009;0.415) or group by emotional distracter valence by working memory loading (<italic>p</italic>&#x02009;=&#x02009;0.491). Such results are confirmatory that participants were paying attention to the task and any differences in brain functioning elicited during the task are not due to differential inability to complete the task.</p></sec><sec id="S5-2"><title>Posttreatment Effects of CET on Frontolimbic and Striatal Brain Functioning During Effortful Emotion Regulation</title><p>Region-of-interest voxel-based analyses were conducted using a 2 (CET vs. TAU)&#x02009;&#x000d7;&#x02009;3 (happy vs. no face, fearful vs. no face, and neutral vs. no face) general linear model to investigate posttreatment brain differences between CET and TAU participants during effortful emotion regulation. No significant interaction effects were observed with regard to the emotional distracter conditions, and thus the main effects of treatment group were examined. Compared to the TAU group, CET participants displayed significantly greater activation during the emotion regulation task in a large cluster involving the left inferior orbital frontal, insula, and ventromedial prefrontal cortices (Table <xref ref-type="table" rid="T2">2</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>). Participants treated with CET, compared to TAU, also had significantly greater emotion regulation-related activation in the right DLPFC, right anterior cingulate cortex, right putamen, bilateral caudate, and in a moderately sized cluster in the right orbital frontal and right ventromedial prefrontal cortices (Table <xref ref-type="table" rid="T2">2</xref>; Figure <xref ref-type="fig" rid="F2">2</xref>). Accordingly, the direction of greater activation related to CET during emotion regulation in the above frontolimbic and striatal regions may be indicative that CET is contributing to neurobiological changes in people with schizophrenia and comorbid substance misuse problems.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><bold>Differential activation during the emotional faces <italic>n</italic>-back task observed between CET and TAU participants at posttreatment</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Region</th><th valign="top" align="left" rowspan="1" colspan="1">BA</th><th valign="top" align="left" rowspan="1" colspan="1">MNI coordinates</th><th valign="top" align="left" rowspan="1" colspan="1">Cluster size</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>z</italic></th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic></th><th valign="top" align="left" rowspan="1" colspan="1">Direction</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">L inferior orbital frontal</td><td align="left" valign="top" rowspan="3" colspan="1">47, 13</td><td align="left" valign="top" rowspan="3" colspan="1">&#x02212;50 24 &#x02212;4</td><td align="left" valign="top" rowspan="3" colspan="1">530</td><td align="left" valign="top" rowspan="3" colspan="1">4.61</td><td align="left" valign="top" rowspan="3" colspan="1">&#x0003c;0.001</td><td align="left" valign="middle" rowspan="3" colspan="1">CET&#x02009;&#x0003e;&#x02009;TAU</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;L insula</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;L ventromedial prefrontal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R putamen/caudate</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">26 22 2</td><td align="left" valign="top" rowspan="1" colspan="1">160</td><td align="left" valign="top" rowspan="1" colspan="1">4.56</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="middle" rowspan="1" colspan="1">CET&#x02009;&#x0003e;&#x02009;TAU</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R inferior/middle/superior orbital frontal</td><td align="left" valign="top" rowspan="2" colspan="1">47</td><td align="left" valign="top" rowspan="2" colspan="1">44 52 &#x02212;2</td><td align="left" valign="top" rowspan="2" colspan="1">91</td><td align="left" valign="top" rowspan="2" colspan="1">3.73</td><td align="left" valign="top" rowspan="2" colspan="1">&#x0003c;0.001</td><td align="left" valign="middle" rowspan="2" colspan="1">CET&#x02009;&#x0003e;&#x02009;TAU</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;R ventromedial prefrontal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R DLPFC</td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">38 24 34</td><td align="left" valign="top" rowspan="1" colspan="1">69</td><td align="left" valign="top" rowspan="1" colspan="1">4.13</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="middle" rowspan="1" colspan="1">CET&#x02009;&#x0003e;&#x02009;TAU</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R anterior cingulate</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">12 52 10</td><td align="left" valign="top" rowspan="1" colspan="1">43</td><td align="left" valign="top" rowspan="1" colspan="1">4.67</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="middle" rowspan="1" colspan="1">CET&#x02009;&#x0003e;&#x02009;TAU</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R DLPFC</td><td align="left" valign="top" rowspan="1" colspan="1">46</td><td align="left" valign="top" rowspan="1" colspan="1">46 40 16</td><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="left" valign="top" rowspan="1" colspan="1">3.49</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="middle" rowspan="1" colspan="1">CET&#x02009;&#x0003e;&#x02009;TAU</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">L caudate</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02013;</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;6 6 8</td><td align="left" valign="top" rowspan="1" colspan="1">37</td><td align="left" valign="top" rowspan="1" colspan="1">3.55</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="middle" rowspan="1" colspan="1">CET&#x02009;&#x0003e;&#x02009;TAU</td></tr></tbody></table><table-wrap-foot><p><italic>BA, Brodmann area; MNI, Montreal Neurological Institute; L, left; R, right; CET, Cognitive Enhancement Therapy; TAU, treatment as usual</italic>.</p><p><italic>Presented results are corrected for multiple comparisons based on 10,000 Monte Carlo simulations executed in AlphaSim (<xref rid="B55" ref-type="bibr">55</xref>) using 3dClustSim (&#x003b1;-level of 0.05, <italic>k</italic>&#x02009;=&#x02009;34, uncorrected <italic>p</italic> of 0.001)</italic>.</p></table-wrap-foot></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Regions of significantly greater activation in participants completing 18&#x02009;months of CET, compared to TAU, during the emotional faces <italic>n</italic>-back task</bold>.</p></caption><graphic xlink:href="fpsyt-06-00186-g002"/></fig></sec><sec id="S5-3"><title>Association Between Posttreatment Brain Functioning During Emotion Regulation and Longitudinal Improvements in Emotion Processing Behavioral Performance</title><p>Greater posttreatment activation during the effortful regulation of emotion in all regions observed to be significantly different between CET and TAU participants (Table <xref ref-type="table" rid="T2">2</xref>) were significantly correlated with greater longitudinal improvements in MSCEIT total scores (all <italic>r</italic>&#x02019;s 0.58&#x02013;0.77, all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.030), with the exception of the right DLPFC (BA 46 only). Greater longitudinal improvement on the ER-40 was significantly correlated with greater posttreatment activation in the large cluster involving the left inferior orbital frontal, ventromedial prefrontal, and insula cortices (<italic>r</italic>&#x02009;=&#x02009;0.56, <italic>p</italic>&#x02009;=&#x02009;0.037). Greater activation in the orbital frontal cortex (cluster including the inferior, middle, and superior levels; <italic>r</italic>&#x02009;=&#x02009;0.65, <italic>p</italic>&#x02009;=&#x02009;0.011) and the right DLPFC (BA 9; <italic>r</italic>&#x02009;=&#x02009;0.56, <italic>p</italic>&#x02009;=&#x02009;0.038) was also significantly associated with greater longitudinal improvement on the ER-40. Mediation analyses revealed that, when adjusting for treatment assignment, greater differential emotion regulation-related activation, favoring CET, in the cluster involving the left inferior orbital frontal, ventromedial prefrontal, and insula cortices, had a significant direct effect on improved total scores on the MSCEIT, with this cluster significantly mediating the association between treatment assignment and improved performance on this test (Table <xref ref-type="table" rid="T3">3</xref>). No direct or mediation effects were observed with regard to changes scores on the ER-40.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><bold>Relationships between posttreatment emotion regulation brain functioning and longitudinal changes in behavioral emotion processing performance</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="middle" align="left" colspan="2" rowspan="1">Direct effect</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="middle" align="left" rowspan="1" colspan="1">Mediator effect</th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="left" valign="middle" colspan="6" rowspan="1"><hr/></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">Regional clusters</th><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>B</italic></bold></th><th align="left" valign="middle" rowspan="1" colspan="1">SE</th><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>t</italic></bold></th><th align="left" valign="middle" rowspan="1" colspan="1">df</th><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>p</italic></bold></th><th align="left" valign="middle" rowspan="1" colspan="1"><italic>z</italic><bold>&#x02032;</bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="middle" colspan="6" rowspan="1">&#x00394;MSCEIT total score</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">L inferior orbital frontal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;L insula</td><td align="left" valign="middle" rowspan="1" colspan="1">14.3</td><td align="left" valign="middle" rowspan="1" colspan="1">4.3</td><td align="left" valign="middle" rowspan="1" colspan="1">3.3</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.007</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;2.7<xref ref-type="table-fn" rid="tfn2">**</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;L ventromedial prefrontal</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R putamen/caudate</td><td align="left" valign="middle" rowspan="1" colspan="1">5.6</td><td align="left" valign="middle" rowspan="1" colspan="1">3.0</td><td align="left" valign="middle" rowspan="1" colspan="1">1.9</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.086</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;1.7<xref ref-type="table-fn" rid="tfn3"><sup>+</sup></xref></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R inferior/middle/superior orbital frontal</td><td align="left" valign="middle" rowspan="2" colspan="1">3.1</td><td align="left" valign="middle" rowspan="2" colspan="1">2.1</td><td align="left" valign="middle" rowspan="2" colspan="1">1.5</td><td align="left" valign="middle" rowspan="2" colspan="1">11</td><td align="left" valign="middle" rowspan="2" colspan="1">0.169</td><td align="left" valign="middle" rowspan="2" colspan="1">&#x02212;1.2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R ventromedial prefrontal</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R DLPFC (BA 9)</td><td align="left" valign="middle" rowspan="1" colspan="1">3.7</td><td align="left" valign="middle" rowspan="1" colspan="1">2.2</td><td align="left" valign="middle" rowspan="1" colspan="1">1.7</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.116</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;1.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R anterior cingulate</td><td align="left" valign="middle" rowspan="1" colspan="1">4.3</td><td align="left" valign="middle" rowspan="1" colspan="1">2.8</td><td align="left" valign="middle" rowspan="1" colspan="1">1.5</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.155</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;1.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R DLPFC (BA 46)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.4</td><td align="left" valign="middle" rowspan="1" colspan="1">5.9</td><td align="left" valign="middle" rowspan="1" colspan="1">0.2</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.813</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;0.2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">L caudate</td><td align="left" valign="middle" rowspan="1" colspan="1">2.8</td><td align="left" valign="middle" rowspan="1" colspan="1">1.4</td><td align="left" valign="middle" rowspan="1" colspan="1">2.1</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.062</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;1.8<xref ref-type="table-fn" rid="tfn3"><sup>+</sup></xref></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="center" valign="middle" colspan="6" rowspan="1">&#x00394;ER-40 correct responses</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">L inferior orbital frontal</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;L insula</td><td align="left" valign="middle" rowspan="1" colspan="1">1.6</td><td align="left" valign="middle" rowspan="1" colspan="1">1.3</td><td align="left" valign="middle" rowspan="1" colspan="1">1.2</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.251</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;1.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;L ventromedial prefrontal</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R putamen/caudate</td><td align="left" valign="middle" rowspan="1" colspan="1">0.4</td><td align="left" valign="middle" rowspan="1" colspan="1">0.8</td><td align="left" valign="middle" rowspan="1" colspan="1">0.6</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.578</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;0.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R inferior/middle/superior orbital frontal</td><td align="left" valign="middle" rowspan="2" colspan="1">0.9</td><td align="left" valign="middle" rowspan="2" colspan="1">0.5</td><td align="left" valign="middle" rowspan="2" colspan="1">2.0</td><td align="left" valign="middle" rowspan="2" colspan="1">11</td><td align="left" valign="middle" rowspan="2" colspan="1">0.072</td><td align="left" valign="middle" rowspan="2" colspan="1">&#x02212;1.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R ventromedial prefrontal</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R DLPFC (BA 9)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.7</td><td align="left" valign="middle" rowspan="1" colspan="1">0.5</td><td align="left" valign="middle" rowspan="1" colspan="1">1.3</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.206</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;1.1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R anterior cingulate</td><td align="left" valign="middle" rowspan="1" colspan="1">0.2</td><td align="left" valign="middle" rowspan="1" colspan="1">0.7</td><td align="left" valign="middle" rowspan="1" colspan="1">0.3</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.764</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;0.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R DLPFC (BA 46)</td><td align="left" valign="middle" rowspan="1" colspan="1">1.4</td><td align="left" valign="middle" rowspan="1" colspan="1">1.3</td><td align="left" valign="middle" rowspan="1" colspan="1">1.1</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.292</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;0.9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">L caudate</td><td align="left" valign="middle" rowspan="1" colspan="1">0.3</td><td align="left" valign="middle" rowspan="1" colspan="1">0.4</td><td align="left" valign="middle" rowspan="1" colspan="1">0.8</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td><td align="left" valign="middle" rowspan="1" colspan="1">0.443</td><td align="left" valign="middle" rowspan="1" colspan="1">&#x02212;0.8</td></tr></tbody></table><table-wrap-foot><p><italic>L, left; R, right; DLPFC, dorsal lateral prefrontal cortex; MSCEIT, The Mayer&#x02013;Salovey&#x02013;Caruso Emotional Intelligence Test; ER-40, Penn Emotion Recognition Test-40</italic>.</p><fn id="tfn2"><p><italic>**<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01</italic>.</p></fn><fn id="tfn3"><p><italic><sup>+</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;1.00</italic>.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="S6"><title>Discussion</title><p>Substance misuse among people with schizophrenia, especially for alcohol and cannabis (<xref rid="B2" ref-type="bibr">2</xref>), is a common, significant problem as addiction is associated with more severe illness trajectories (<xref rid="B11" ref-type="bibr">11</xref>) and worse community functioning (<xref rid="B6" ref-type="bibr">6</xref>). Poor emotion regulation may be a key contributor of elevating the risk for substance misuse in individuals with schizophrenia (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Neural correlates of disrupted emotion regulation in individuals with schizophrenia and substance misuse problems (<xref rid="B52" ref-type="bibr">52</xref>) have been shown to include frontal, limbic, and striatal regions important for emotional neurocircuitry (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B36" ref-type="bibr">36</xref>). Recently, significant improvements in emotion regulation abilities were observed in individuals with schizophrenia who also misuse alcohol and/or cannabis after being treated with CET, a cognitive remediation intervention (<xref rid="B18" ref-type="bibr">18</xref>). Therefore, this original, exploratory study sought to examine differences in brain functioning during effortful emotion regulation in participants with comorbid schizophrenia and alcohol and/or cannabis misuse following CET or TAU. The direct and mediation effects of these neurobiological differences on longitudinal changes in behavioral emotion processing outcomes were also examined.</p><p>Compared to participants in TAU, CET participants displayed significantly greater activation in frontal, limbic, and striatal networks involved in the regulation of emotion at posttreatment (<xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B63" ref-type="bibr">63</xref>), including the DLPFC, ventromedial prefrontal cortex, orbital frontal cortex, anterior cingulate, insula, caudate, and putamen. No significant interactions were observed regarding emotional valence during the emotional faces <italic>n</italic>-back task. Longitudinal improvements in behavioral emotion processing abilities were correlated with greater activation in the majority of these above regions. Interestingly, a mediating effect was observed in an area including the orbital frontal cortex, ventromedial prefrontal cortex, and the insula such that greater brain activation in these regions mediated longitudinal improvements in behavioral emotion processing abilities.</p><p>Such results suggest that treatment with CET (<xref rid="B18" ref-type="bibr">18</xref>) may be normalizing the coordination and function of frontolimbic and striatal regions involved in emotion regulation in individuals with schizophrenia who also misuse alcohol and/or cannabis. This is evidenced by research demonstrating that communication of prefrontal and limbic regions modulates cognitive control over emotion regulation abilities (<xref rid="B64" ref-type="bibr">64</xref>&#x02013;<xref rid="B66" ref-type="bibr">66</xref>), which has been observed to be dysregulated in individuals with schizophrenia (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>). It may be that improved cognitive functioning gained through CET (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B70" ref-type="bibr">70</xref>) increased participants&#x02019; ability to regulate and manage their emotional states. Meta-analytic evidence has shown that cognitive remediation interventions have a common neural plasticity effect of increasing activation in frontal and limbic regions that are related to improved cognitive and socio-emotional functioning in individuals with schizophrenia (<xref rid="B27" ref-type="bibr">27</xref>). The findings from this investigation of increased task-related activation in some overlapping frontolimbic regions are supportive of CET as an effective intervention for supporting functional recovery of this underserved, vulnerable population.</p><p>Of course, these findings have many caveats that preclude firm conclusions regarding causality of treatment efficacy. The first limitation is the very small sample size employed in this research, particularly in the TAU condition. This may explain the lack of significant emotional valence interactions with group assignment from the emotional faces <italic>n</italic>-back task, although sufficient power was available to detect the very large effects observed in frontolimbic brain functioning. Also related to the small sample size, the groups were not perfectly matched especially with regard to age and race. Although age and race were not significantly different between the groups, we did include them as possible confounders in all analyses examining differential effects of treatment on brain functioning. Noteworthy, CET had a higher, but non-significantly different attrition rate compared to TAU in the larger feasibility trial [for a further description, see Eack et al. (<xref rid="B18" ref-type="bibr">18</xref>)]. Next, because the imaging component was an opportunistic add-on study funded near the completion of the parent clinical trial, no pretreatment imaging data were available. Posttreatment randomized-controlled trials are common and protect against many threats to internal validity (<xref rid="B71" ref-type="bibr">71</xref>), but in the case of quantitative outcomes with unknown baseline values, they are unable to determine the magnitude of change. We suspect that the greater brain activation observed in CET during emotion regulation is reflective of longitudinal increases in frontolimbic activity. However, in the absence of an active comparison group, such findings may also reflect non-specific CET effects associated with more therapeutic contacts, including group activities. Further, retention of participants for fMRI procedures was greater in CET than TAU, which may have impacted the results by limiting the sample of TAU participants. However, there were no significant differences in baseline characteristics observed between TAU participants who did vs. did not complete an fMRI scan (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.166). In addition, we did not assess participants level of alcohol and/or cannabis use at the time of posttreatment scanning or during assessments of emotion processing, which could have influenced brain functioning and performance. It will be important for future studies to employ longitudinal imaging methods and assess substance misuse at the time of assessments to address these issues, and until these findings can be replicated in adequately powered samples they should be considered tentative and interpreted with caution. It will also be important for future research with larger sample sizes to examine the implications of such findings on symptom severity and other functional outcomes in the illness.</p><p>In summary, this preliminary study was the first to show a possible neural plasticity relationship between CET and emotion regulation-related brain functioning in individuals with schizophrenia and alcohol and/or cannabis misuse comorbidities participating in a randomized clinical trial. The findings indicated that CET may lead to differential changes in functioning of frontolimbic and striatal regions implicated in the regulation of emotion. Increased activation in these regions during effortful emotion regulation was supportive of longitudinal improvements in behavioral emotion processing abilities. Improved emotion regulation may serve as a protective factor for substance misuse as well as play a role in improved interpersonal and other psychosocial functioning. The findings from this investigation are not only informative for future research but also highlight the utility of providing cognitive remediation interventions, such as CET, to optimize recovery for people with schizophrenia who have substance misuse problems, particularly for alcohol and cannabis.</p></sec><sec id="S7"><title>Author Contributions</title><p>JW, SH, JC, MP, MK, CN, and SE all made substantial contribution to this manuscript.</p></sec><sec id="S8"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><sec id="S9"><title>Funding</title><p>Funding for this research was provided by NIH grants DA-30763 (SE), MH-95783 (SE), and RR-24154 (SE).</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>O</given-names></name><name><surname>Teesson</surname><given-names>M</given-names></name><name><surname>Slade</surname><given-names>T</given-names></name><name><surname>Hasin</surname><given-names>D</given-names></name><name><surname>Degenhardt</surname><given-names>L</given-names></name><name><surname>Baillie</surname><given-names>A</given-names></name></person-group>. <article-title>Further evidence of differences in substance use and dependence between Australia and the United States</article-title>. <source>Drug Alcohol Depend</source> (<year>2009</year>) <volume>100</volume>(<issue>3</issue>):<fpage>258</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2008.10.011</pub-id><pub-id pub-id-type="pmid">19042096</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group>
<article-title>Substance use disorders in schizophrenia&#x02009;&#x02013;&#x02009;clinical implications of comorbidity</article-title>. <source>Schizophr Bull</source> (<year>2009</year>) <volume>35</volume>(<issue>3</issue>):<fpage>469</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbp016</pub-id><pub-id pub-id-type="pmid">19325163</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>JJ</given-names></name><name><surname>Brown</surname><given-names>SA</given-names></name><name><surname>Horan</surname><given-names>WP</given-names></name><name><surname>Sherwood</surname><given-names>AR</given-names></name></person-group>. <article-title>Substance use disorders in schizophrenia: review, integration, and a proposed model</article-title>. <source>Clin Psychol Rev</source> (<year>2000</year>) <volume>20</volume>(<issue>2</issue>):<fpage>207</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1016/S0272-7358(99)00033-1</pub-id><pub-id pub-id-type="pmid">10721498</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>JJ</given-names></name><name><surname>Squires</surname><given-names>D</given-names></name><name><surname>Henry</surname><given-names>T</given-names></name><name><surname>Horan</surname><given-names>WP</given-names></name><name><surname>Bogenschutz</surname><given-names>M</given-names></name><name><surname>Lauriello</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Examining an affect regulation model of substance abuse in schizophrenia: the role of traits and coping</article-title>. <source>J Nerv Ment Dis</source> (<year>1999</year>) <volume>187</volume>(<issue>2</issue>):<fpage>72</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1097/00005053-199902000-00002</pub-id><pub-id pub-id-type="pmid">10067946</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregg</surname><given-names>L</given-names></name><name><surname>Barrowclough</surname><given-names>C</given-names></name><name><surname>Haddock</surname><given-names>G</given-names></name></person-group>. <article-title>Reasons for increased substance use in psychosis</article-title>. <source>Clin Psychol Rev</source> (<year>2007</year>) <volume>27</volume>(<issue>4</issue>):<fpage>494</fpage>&#x02013;<lpage>510</lpage>.<pub-id pub-id-type="doi">10.1016/j.cpr.2006.09.004</pub-id><pub-id pub-id-type="pmid">17240501</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>L</given-names></name></person-group>. <article-title>Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes</article-title>. <source>Schizophr Res</source> (<year>1999</year>) <volume>35</volume>:<fpage>S93</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="doi">10.1016/S0920-9964(98)00161-3</pub-id><pub-id pub-id-type="pmid">10190230</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerfoot</surname><given-names>KE</given-names></name><name><surname>Rosenheck</surname><given-names>RA</given-names></name><name><surname>Petrakis</surname><given-names>IL</given-names></name><name><surname>Swartz</surname><given-names>MS</given-names></name><name><surname>Keefe</surname><given-names>RS</given-names></name><name><surname>McEvoy</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>Substance use and schizophrenia: adverse correlates in the CATIE study sample</article-title>. <source>Schizophr Res</source> (<year>2011</year>) <volume>132</volume>(<issue>2</issue>):<fpage>177</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2011.07.032</pub-id><pub-id pub-id-type="pmid">21872443</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>GE</given-names></name><name><surname>Bergen</surname><given-names>J</given-names></name><name><surname>Bashir</surname><given-names>M</given-names></name></person-group>. <article-title>Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse</article-title>. <source>Schizophr Res</source> (<year>2002</year>) <volume>54</volume>(<issue>3</issue>):<fpage>253</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1016/S0920-9964(01)00261-4</pub-id><pub-id pub-id-type="pmid">11950550</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>DO</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Weiden</surname><given-names>PJ</given-names></name><name><surname>McEvoy</surname><given-names>JP</given-names></name><name><surname>Hamer</surname><given-names>RM</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name></person-group>. <article-title>Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study</article-title>. <source>J Clin Psychiatry</source> (<year>2008</year>) <volume>69</volume>(<issue>1</issue>):<fpage>106</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.4088/JCP.v69n0114</pub-id><pub-id pub-id-type="pmid">18312044</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swofford</surname><given-names>CD</given-names></name><name><surname>Kasckow</surname><given-names>JW</given-names></name><name><surname>Scheller-Gilkey</surname><given-names>G</given-names></name><name><surname>Inderbitzin</surname><given-names>LB</given-names></name></person-group>. <article-title>Substance use: a powerful predictor of relapse in schizophrenia</article-title>. <source>Schizophr Res</source> (<year>1996</year>) <volume>20</volume>(<issue>1</issue>):<fpage>145</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1016/0920-9964(95)00068-2</pub-id><pub-id pub-id-type="pmid">8794502</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>LM</given-names></name><name><surname>Hesse</surname><given-names>M</given-names></name><name><surname>Lykke</surname><given-names>J</given-names></name></person-group>
<article-title>The impact of substance use disorders on the course of schizophrenia&#x02009;&#x02013;&#x02009;a 15-year follow-up study: dual diagnosis over 15 years</article-title>. <source>Schizophr Res</source> (<year>2011</year>) <volume>130</volume>(<issue>1&#x02013;3</issue>):<fpage>228</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2011.04.011</pub-id><pub-id pub-id-type="pmid">21592731</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunette</surname><given-names>MF</given-names></name><name><surname>Mueser</surname><given-names>KT</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Drake</surname><given-names>RE</given-names></name></person-group>. <article-title>Relationships between symptoms of schizophrenia and substance abuse</article-title>. <source>J Nerv Ment Dis</source> (<year>1997</year>) <volume>185</volume>(<issue>1</issue>):<fpage>13</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1097/00005053-199701000-00003</pub-id><pub-id pub-id-type="pmid">9040528</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talamo</surname><given-names>A</given-names></name><name><surname>Centorrino</surname><given-names>F</given-names></name><name><surname>Tondo</surname><given-names>L</given-names></name><name><surname>Dimitri</surname><given-names>A</given-names></name><name><surname>Hennen</surname><given-names>J</given-names></name><name><surname>Baldessarini</surname><given-names>RJ</given-names></name></person-group>. <article-title>Comorbid substance-use in schizophrenia: relation to positive and negative symptoms</article-title>. <source>Schizophr Res</source> (<year>2006</year>) <volume>86</volume>(<issue>1&#x02013;3</issue>):<fpage>251</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2006.04.004</pub-id><pub-id pub-id-type="pmid">16750347</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueser</surname><given-names>KT</given-names></name><name><surname>McGurk</surname><given-names>SR</given-names></name></person-group>
<article-title>Cognitive functioning in schizophrenia and co-occurring substance use disorder: where do we go from here?</article-title>
<source>J Dual Diagn</source> (<year>2012</year>) <volume>8</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1080/15504263.2012.648435</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnell</surname><given-names>T</given-names></name><name><surname>Koethe</surname><given-names>D</given-names></name><name><surname>Daumann</surname><given-names>J</given-names></name><name><surname>Gouzoulis-Mayfrank</surname><given-names>E</given-names></name></person-group>. <article-title>The role of cannabis in cognitive functioning of patients with schizophrenia</article-title>. <source>Psychopharmacology</source> (<year>2009</year>) <volume>205</volume>(<issue>1</issue>):<fpage>45</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-009-1512-9</pub-id><pub-id pub-id-type="pmid">19326102</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>V</given-names></name><name><surname>Betteridge</surname><given-names>S</given-names></name><name><surname>Wanigaratne</surname><given-names>S</given-names></name><name><surname>Best</surname><given-names>D</given-names></name><name><surname>Strang</surname><given-names>J</given-names></name><name><surname>Gossop</surname><given-names>M</given-names></name></person-group>. <article-title>Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use disorder</article-title>. <source>Schizophr Res</source> (<year>2009</year>) <volume>114</volume>(<issue>1&#x02013;3</issue>):<fpage>98</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2009.05.020</pub-id><pub-id pub-id-type="pmid">19540724</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hogarty</surname><given-names>GE</given-names></name><name><surname>Greenwald</surname><given-names>DP</given-names></name></person-group>
<source>Cognitive Enhancement Therapy: the Training Manual</source>. <publisher-name>University of Pittsburgh Medical Center</publisher-name> (<year>2006</year>). Available from: <uri xlink:type="simple" xlink:href="http://www.CognitiveEnhancementTherapy.com">www.CognitiveEnhancementTherapy.com</uri></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eack</surname><given-names>SM</given-names></name><name><surname>Hogarty</surname><given-names>SS</given-names></name><name><surname>Greenwald</surname><given-names>DP</given-names></name><name><surname>Litschge</surname><given-names>MY</given-names></name><name><surname>McKnight</surname><given-names>SAF</given-names></name><name><surname>Bangalore</surname><given-names>SS</given-names></name><etal/></person-group>
<article-title>Cognitive enhancement therapy in substance misusing schizophrenia: results of an 18-month feasibility trial</article-title>. <source>Schizophr Res</source> (<year>2015</year>) <volume>161</volume>(<issue>2&#x02013;3</issue>):<fpage>478</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2014.11.017</pub-id><pub-id pub-id-type="pmid">25510926</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eack</surname><given-names>S</given-names></name></person-group>. <article-title>Cognitive remediation: a new generation of psychosocial interventions for people with schizophrenia</article-title>. <source>Soc Work</source> (<year>2012</year>) <volume>57</volume>(<issue>3</issue>):<fpage>235</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1093/sw/sws008</pub-id><pub-id pub-id-type="pmid">23252315</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>L</given-names></name><name><surname>Haas</surname><given-names>G</given-names></name><name><surname>Weiden</surname><given-names>P</given-names></name><name><surname>Sweeney</surname><given-names>J</given-names></name><name><surname>Frances</surname><given-names>A</given-names></name></person-group>. <article-title>Acute effects of drug abuse in schizophrenic patients: clinical observations and patients&#x02019; self-reports</article-title>. <source>Schizophr Bull</source> (<year>1990</year>) <volume>16</volume>(<issue>1</issue>):<fpage>69</fpage>.<pub-id pub-id-type="doi">10.1093/schbul/16.1.69</pub-id><pub-id pub-id-type="pmid">2185536</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>L</given-names></name><name><surname>Haas</surname><given-names>G</given-names></name><name><surname>Weiden</surname><given-names>PJ</given-names></name><name><surname>Sweeney</surname><given-names>J</given-names></name><name><surname>Frances</surname><given-names>AJ</given-names></name></person-group>. <article-title>Drug abuse in schizophrenic patients: clinical correlates and reasons for use</article-title>. <source>Am J Psychiatry</source> (<year>1991</year>) <volume>148</volume>(<issue>2</issue>):<fpage>224</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">1987823</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>RJ</given-names></name><name><surname>Jackson</surname><given-names>DC</given-names></name><name><surname>Kalin</surname><given-names>NH</given-names></name></person-group>. <article-title>Emotion, plasticity, context, and regulation: perspectives from affective neuroscience</article-title>. <source>Psychol Bull</source> (<year>2000</year>) <volume>126</volume>(<issue>6</issue>):<fpage>890</fpage>.<pub-id pub-id-type="doi">10.1037/0033-2909.126.6.890</pub-id><pub-id pub-id-type="pmid">11107881</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldin</surname><given-names>PR</given-names></name><name><surname>McRae</surname><given-names>K</given-names></name><name><surname>Ramel</surname><given-names>W</given-names></name><name><surname>Gross</surname><given-names>JJ</given-names></name></person-group>. <article-title>The neural bases of emotion regulation: reappraisal and suppression of negative emotion</article-title>. <source>Biol Psychiatry</source> (<year>2008</year>) <volume>63</volume>(<issue>6</issue>):<fpage>577</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.05.031</pub-id><pub-id pub-id-type="pmid">17888411</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>ML</given-names></name><name><surname>Drevets</surname><given-names>WC</given-names></name><name><surname>Rauch</surname><given-names>SL</given-names></name><name><surname>Lane</surname><given-names>R</given-names></name></person-group>. <article-title>Neurobiology of emotion perception I: the neural basis of normal emotion perception</article-title>. <source>Biol Psychiatry</source> (<year>2003</year>) <volume>54</volume>(<issue>5</issue>):<fpage>504</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1016/S0006-3223(03)00168-9</pub-id><pub-id pub-id-type="pmid">12946879</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>RZ</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group>. <article-title>Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications</article-title>. <source>Nat Rev Neurosci</source> (<year>2011</year>) <volume>12</volume>(<issue>11</issue>):<fpage>652</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="doi">10.1038/nrn3119</pub-id><pub-id pub-id-type="pmid">22011681</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>RA</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name><name><surname>Self</surname><given-names>DW</given-names></name></person-group>
<article-title>A neurobiological basis for substance abuse comorbidity in schizophrenia</article-title>. <source>Biol Psychiatry</source> (<year>2001</year>) <volume>50</volume>(<issue>2</issue>):<fpage>71</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1016/S0006-3223(01)01134-9</pub-id><pub-id pub-id-type="pmid">11526998</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>IS</given-names></name><name><surname>MacDonald</surname><given-names>AW</given-names></name></person-group>
<article-title>Brain correlates of cognitive remediation in schizo&#x000ad;phrenia: activation likelihood analysis shows preliminary evidence of neural target engagement</article-title>. <source>Schizophr Bull</source> (<year>2015</year>) <volume>41</volume>(<issue>6</issue>):<fpage>1276</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbv025</pub-id><pub-id pub-id-type="pmid">25800249</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eack</surname><given-names>SM</given-names></name><name><surname>Hogarty</surname><given-names>GE</given-names></name><name><surname>Cho</surname><given-names>RY</given-names></name><name><surname>Prasad</surname><given-names>KM</given-names></name><name><surname>Greenwald</surname><given-names>DP</given-names></name><name><surname>Hogarty</surname><given-names>SS</given-names></name><etal/></person-group>
<article-title>Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial</article-title>. <source>Arch Gen Psychiatry</source> (<year>2010</year>) <volume>67</volume>(<issue>7</issue>):<fpage>674</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.63</pub-id><pub-id pub-id-type="pmid">20439824</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keshavan</surname><given-names>MS</given-names></name><name><surname>Vinogradov</surname><given-names>S</given-names></name><name><surname>Rumsey</surname><given-names>J</given-names></name><name><surname>Sherrill</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>A</given-names></name></person-group>. <article-title>Cognitive training in mental disorders: update and future directions</article-title>. <source>Am J Psychiatry</source> (<year>2014</year>) <volume>171</volume>(<issue>5</issue>):<fpage>510</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1176/appi.ajp.2013.13081075</pub-id><pub-id pub-id-type="pmid">24700194</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Gibbon</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>JBW</given-names></name></person-group>
<source>Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Biometrics Research, New York State Psychiatric Institute</publisher-name> (<year>2002</year>).</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogarty</surname><given-names>GE</given-names></name><name><surname>Flesher</surname><given-names>S</given-names></name><name><surname>Ulrich</surname><given-names>R</given-names></name><name><surname>Carter</surname><given-names>M</given-names></name><name><surname>Greenwald</surname><given-names>D</given-names></name><name><surname>Pogue-Geile</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior</article-title>. <source>Arch Gen Psychiatry</source> (<year>2004</year>) <volume>61</volume>(<issue>9</issue>):<fpage>866</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.61.9.866</pub-id><pub-id pub-id-type="pmid">15351765</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLellan</surname><given-names>AT</given-names></name><name><surname>Luborsky</surname><given-names>L</given-names></name><name><surname>Woody</surname><given-names>GE</given-names></name><name><surname>O&#x02019;BRIEN</surname><given-names>CP</given-names></name></person-group>. <article-title>An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index</article-title>. <source>J Nerv Ment Dis</source> (<year>1980</year>) <volume>168</volume>(<issue>1</issue>):<fpage>26</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1097/00005053-198001000-00006</pub-id><pub-id pub-id-type="pmid">7351540</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juckel</surname><given-names>G</given-names></name><name><surname>Schlagenhauf</surname><given-names>F</given-names></name><name><surname>Koslowski</surname><given-names>M</given-names></name><name><surname>Filonov</surname><given-names>D</given-names></name><name><surname>W&#x000fc;stenberg</surname><given-names>T</given-names></name><name><surname>Villringer</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics</article-title>. <source>Psychopharmacology</source> (<year>2006</year>) <volume>187</volume>(<issue>2</issue>):<fpage>222</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-006-0405-4</pub-id><pub-id pub-id-type="pmid">16721614</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladouceur</surname><given-names>CD</given-names></name><name><surname>Silk</surname><given-names>JS</given-names></name><name><surname>Dahl</surname><given-names>RE</given-names></name><name><surname>Ostapenko</surname><given-names>L</given-names></name><name><surname>Kronhaus</surname><given-names>DM</given-names></name><name><surname>Phillips</surname><given-names>ML</given-names></name></person-group>. <article-title>Fearful faces influence attentional control processes in anxious youth and adults</article-title>. <source>Emotion</source> (<year>2009</year>) <volume>9</volume>(<issue>6</issue>):<fpage>855</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1037/a0017747</pub-id><pub-id pub-id-type="pmid">20001128</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tottenham</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>JW</given-names></name><name><surname>Leon</surname><given-names>AC</given-names></name><name><surname>McCarry</surname><given-names>T</given-names></name><name><surname>Nurse</surname><given-names>M</given-names></name><name><surname>Hare</surname><given-names>TA</given-names></name><etal/></person-group>
<article-title>The NimStim set of facial expressions: judgments from untrained research participants</article-title>. <source>Psychiatry Res</source> (<year>2009</year>) <volume>168</volume>(<issue>3</issue>):<fpage>242</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2008.05.006</pub-id><pub-id pub-id-type="pmid">19564050</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>ML</given-names></name><name><surname>Ladouceur</surname><given-names>CD</given-names></name><name><surname>Drevets</surname><given-names>WC</given-names></name></person-group>. <article-title>A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder</article-title>. <source>Mol Psychiatry</source> (<year>2008</year>) <volume>13</volume>(<issue>9</issue>):<fpage>833</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1038/mp.2008.65</pub-id><pub-id pub-id-type="pmid">18574483</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Whitfield-Gabrieli</surname><given-names>S</given-names></name></person-group>
<source>Artifact Detection Tools</source>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Massachusetts Institute of Technology</publisher-name> (<year>2011</year>).</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>JD</given-names></name><name><surname>Salovey</surname><given-names>P</given-names></name><name><surname>Caruso</surname><given-names>DR</given-names></name><name><surname>Sitarenios</surname><given-names>G</given-names></name></person-group>. <article-title>Measuring emotional intelligence with the MSCEIT V2. 0</article-title>. <source>Emotion</source> (<year>2003</year>) <volume>3</volume>(<issue>1</issue>):<fpage>97</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="doi">10.1037/1528-3542.3.1.97</pub-id><pub-id pub-id-type="pmid">12899321</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohler</surname><given-names>CG</given-names></name><name><surname>Turner</surname><given-names>TH</given-names></name><name><surname>Bilker</surname><given-names>WB</given-names></name><name><surname>Brensinger</surname><given-names>CM</given-names></name><name><surname>Siegel</surname><given-names>SJ</given-names></name><name><surname>Kanes</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>Facial emotion recognition in schizophrenia: intensity effects and error pattern</article-title>. <source>Am J Psychiatry</source> (<year>2003</year>) <volume>160</volume>(<issue>10</issue>):<fpage>1768</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1176/appi.ajp.160.10.1768</pub-id><pub-id pub-id-type="pmid">14514489</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojtalik</surname><given-names>JA</given-names></name><name><surname>Eack</surname><given-names>SM</given-names></name><name><surname>Keshavan</surname><given-names>MS</given-names></name></person-group>
<article-title>Structural neurobiological correlates of Mayer&#x02013;Salovey&#x02013;Caruso emotional intelligence test performance in early course schizophrenia</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> (<year>2013</year>) <volume>40</volume>:<fpage>207</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.09.013</pub-id><pub-id pub-id-type="pmid">23041620</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gur</surname><given-names>RC</given-names></name><name><surname>Schroeder</surname><given-names>L</given-names></name><name><surname>Turner</surname><given-names>T</given-names></name><name><surname>McGrath</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>RM</given-names></name><name><surname>Turetsky</surname><given-names>BI</given-names></name><etal/></person-group>
<article-title>Brain activation during facial emotion processing</article-title>. <source>Neuroimage</source> (<year>2002</year>) <volume>16</volume>(<issue>3</issue>):<fpage>651</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1006/nimg.2002.1097</pub-id><pub-id pub-id-type="pmid">12169250</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Mayer</surname><given-names>JD</given-names></name><name><surname>Salovey</surname><given-names>P</given-names></name></person-group>, editors. <source>What is Emotional Intelligence?</source>
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Basic Books</publisher-name> (<year>1997</year>).</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuechterlein</surname><given-names>KH</given-names></name><name><surname>Green</surname><given-names>MF</given-names></name><name><surname>Kern</surname><given-names>RS</given-names></name><name><surname>Baade</surname><given-names>LE</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name><name><surname>Cohen</surname><given-names>JD</given-names></name><etal/></person-group>
<article-title>The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity</article-title>. <source>Am J Psychiatry</source> (<year>2008</year>) <volume>165</volume>(<issue>2</issue>):<fpage>203</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1176/appi.ajp.2007.07010042</pub-id><pub-id pub-id-type="pmid">18172019</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eack</surname><given-names>SM</given-names></name><name><surname>Greeno</surname><given-names>CG</given-names></name><name><surname>Pogue-Geile</surname><given-names>MF</given-names></name><name><surname>Newhill</surname><given-names>CE</given-names></name><name><surname>Hogarty</surname><given-names>GE</given-names></name><name><surname>Keshavan</surname><given-names>MS</given-names></name></person-group>
<article-title>Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso emotional intelligence test</article-title>. <source>Schizophr Bull</source> (<year>2010</year>) <volume>36</volume>(<issue>2</issue>):<fpage>370</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbn091</pub-id><pub-id pub-id-type="pmid">18648021</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>CS</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name><name><surname>Gur</surname><given-names>R</given-names></name><name><surname>Gur</surname><given-names>R</given-names></name><name><surname>Pinkham</surname><given-names>A</given-names></name><name><surname>Ochsner</surname><given-names>K</given-names></name></person-group>
<article-title>CNTRICS final task selection: social cognitive and affective neuroscience-based measures</article-title>. <source>Schizophr Bull</source> (<year>2009</year>) <volume>35</volume>(<issue>1</issue>):<fpage>153</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbn157</pub-id><pub-id pub-id-type="pmid">19011231</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Ben-Yishay</surname><given-names>Y</given-names></name><name><surname>Piasetsky</surname><given-names>EB</given-names></name><name><surname>Rattok</surname><given-names>J</given-names></name></person-group>, editors. <source>A Systematic Method for Ameliorating Disorders in Basic Attention</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Guilford</publisher-name> (<year>1985</year>).</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bracy</surname><given-names>OL</given-names></name></person-group>
<source>PSSCogRehab</source>. <publisher-loc>Indianapolis</publisher-loc>: <publisher-name>Psychological Software Services</publisher-name> (<year>1994</year>).</mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ammons</surname><given-names>RB</given-names></name><name><surname>Ammons</surname><given-names>CH</given-names></name></person-group>
<article-title>The quick test (QT): provisional manual</article-title>. <source>Psychol Rep</source> (<year>1962</year>) <volume>11</volume>(<issue>1</issue>):<fpage>111</fpage>&#x02013;<lpage>61</lpage>.</mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friston</surname><given-names>KJ</given-names></name><name><surname>Stephan</surname><given-names>KE</given-names></name><name><surname>Lund</surname><given-names>TE</given-names></name><name><surname>Morcom</surname><given-names>A</given-names></name><name><surname>Kiebel</surname><given-names>S</given-names></name></person-group>. <article-title>Mixed-effects and fMRI studies</article-title>. <source>Neuroimage</source> (<year>2005</year>) <volume>24</volume>(<issue>1</issue>):<fpage>244</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuroimage.2004.08.055</pub-id><pub-id pub-id-type="pmid">15588616</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldjian</surname><given-names>JA</given-names></name><name><surname>Laurienti</surname><given-names>PJ</given-names></name><name><surname>Kraft</surname><given-names>RA</given-names></name><name><surname>Burdette</surname><given-names>JH</given-names></name></person-group>. <article-title>An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets</article-title>. <source>Neuroimage</source> (<year>2003</year>) <volume>19</volume>(<issue>3</issue>):<fpage>1233</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S1053-8119(03)00169-1</pub-id><pub-id pub-id-type="pmid">12880848</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzourio-Mazoyer</surname><given-names>N</given-names></name><name><surname>Landeau</surname><given-names>B</given-names></name><name><surname>Papathanassiou</surname><given-names>D</given-names></name><name><surname>Crivello</surname><given-names>F</given-names></name><name><surname>Etard</surname><given-names>O</given-names></name><name><surname>Delcroix</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain</article-title>. <source>Neuroimage</source> (<year>2002</year>) <volume>15</volume>(<issue>1</issue>):<fpage>273</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1006/nimg.2001.0978</pub-id><pub-id pub-id-type="pmid">11771995</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancini-Mar&#x000ef;e</surname><given-names>A</given-names></name><name><surname>Potvin</surname><given-names>S</given-names></name><name><surname>Fahim</surname><given-names>C</given-names></name><name><surname>Beauregard</surname><given-names>M</given-names></name><name><surname>Mensour</surname><given-names>B</given-names></name><name><surname>Stip</surname><given-names>E</given-names></name></person-group>. <article-title>Neural correlates of the affect regulation model in schizophrenia patients with substance use history: a functional magnetic resonance imaging study</article-title>. <source>J Clin Psychiatry</source> (<year>2006</year>) <volume>67</volume>(<issue>3</issue>):<fpage>342</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.4088/JCP.v67n0302</pub-id><pub-id pub-id-type="pmid">16649818</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>T</given-names></name><name><surname>Hayasaka</surname><given-names>S</given-names></name></person-group>. <article-title>Controlling the familywise error rate in functional neuroimaging: a comparative review</article-title>. <source>Stat Methods Med Res</source> (<year>2003</year>) <volume>12</volume>(<issue>5</issue>):<fpage>419</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1191/0962280203sm341ra</pub-id><pub-id pub-id-type="pmid">14599004</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>MD</given-names></name><name><surname>Cunningham</surname><given-names>WA</given-names></name></person-group>. <article-title>Type I and type II error concerns in fMRI research: re-balancing the scale</article-title>. <source>Soc Cogn Affect Neurosci</source> (<year>2009</year>) <volume>4</volume>(<issue>4</issue>):<fpage>423</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1093/scan/nsp052</pub-id><pub-id pub-id-type="pmid">20035017</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>BD</given-names></name></person-group>
<source>Simultaneous Inference for fMRI Data</source>. <publisher-loc>Milwaukee, WI</publisher-loc>: <publisher-name>Author</publisher-name> (<year>2000</year>).</mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="book"><collab>R Core Team</collab>. <source>R: A Language and Environment for Statistical Computing</source>. <publisher-loc>Vienna</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name> (<year>2014</year>).</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brett</surname><given-names>M</given-names></name><name><surname>Anton</surname><given-names>J-L</given-names></name><name><surname>Valabregue</surname><given-names>R</given-names></name><name><surname>Poline</surname><given-names>J-B</given-names></name></person-group>
<article-title>Region of interest analysis using an SPM toolbox</article-title>. <source>Neuroimage</source> (<year>2002</year>) <volume>16</volume>(<issue>2 Suppl 1</issue>):<fpage>497</fpage><pub-id pub-id-type="doi">10.1016/S1053-8119(02)90013-3</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>RM</given-names></name><name><surname>Kenny</surname><given-names>DA</given-names></name></person-group>
<article-title>The moderator&#x02013;mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations</article-title>. <source>J Pers Soc Psychol</source> (<year>1986</year>) <volume>51</volume>(<issue>6</issue>):<fpage>1173</fpage><pub-id pub-id-type="doi">10.1037/0022-3514.51.6.1173</pub-id><pub-id pub-id-type="pmid">3806354</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>HC</given-names></name><name><surname>Wilson</surname><given-names>GT</given-names></name><name><surname>Fairburn</surname><given-names>CG</given-names></name><name><surname>Agras</surname><given-names>WS</given-names></name></person-group>. <article-title>Mediators and moderators of treatment effects in randomized clinical trials</article-title>. <source>Arch Gen Psychiatry</source> (<year>2002</year>) <volume>59</volume>(<issue>10</issue>):<fpage>877</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.59.10.877</pub-id><pub-id pub-id-type="pmid">12365874</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tofighi</surname><given-names>D</given-names></name><name><surname>MacKinnon</surname><given-names>DP</given-names></name></person-group>. <article-title>RMediation: an R package for mediation analysis confidence intervals</article-title>. <source>Behav Res Methods</source> (<year>2011</year>) <volume>43</volume>(<issue>3</issue>):<fpage>692</fpage>&#x02013;<lpage>700</lpage>.<pub-id pub-id-type="doi">10.3758/s13428-011-0076-x</pub-id><pub-id pub-id-type="pmid">21487904</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacKinnon</surname><given-names>DP</given-names></name><name><surname>Lockwood</surname><given-names>CM</given-names></name><name><surname>Hoffman</surname><given-names>JM</given-names></name><name><surname>West</surname><given-names>SG</given-names></name><name><surname>Sheets</surname><given-names>V</given-names></name></person-group>
<article-title>A comparison of methods to test mediation and other intervening variable effects</article-title>. <source>Psychol Methods</source> (<year>2002</year>) <volume>7</volume>(<issue>1</issue>):<fpage>83</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="doi">10.1037/1082-989X.7.1.83</pub-id><pub-id pub-id-type="pmid">11928892</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dempster</surname><given-names>AP</given-names></name><name><surname>Laird</surname><given-names>NM</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group>
<article-title>Maximum likelihood from incomplete data via the EM algorithm</article-title>. <source>J R Stat Soc Series B Methodol</source> (<year>1977</year>) <volume>39</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>38</lpage>.</mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>ML</given-names></name><name><surname>Drevets</surname><given-names>WC</given-names></name><name><surname>Rauch</surname><given-names>SL</given-names></name><name><surname>Lane</surname><given-names>R</given-names></name></person-group>. <article-title>Neurobiology of emotion perception II: implications for major psychiatric disorders</article-title>. <source>Biol Psychiatry</source> (<year>2003</year>) <volume>54</volume>(<issue>5</issue>):<fpage>515</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="doi">10.1016/S0006-3223(03)00171-9</pub-id><pub-id pub-id-type="pmid">12946880</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>MJ</given-names></name><name><surname>Malhi</surname><given-names>GS</given-names></name></person-group>
<article-title>Neural mechanisms of the cognitive control of emotion</article-title>. <source>Acta Neuropsychiatr</source> (<year>2006</year>) <volume>18</volume>(<issue>3&#x02013;4</issue>):<fpage>144</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1111/j.1601-5215.2006.00149.x</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochsner</surname><given-names>KN</given-names></name><name><surname>Silvers</surname><given-names>JA</given-names></name><name><surname>Buhle</surname><given-names>JT</given-names></name></person-group>. <article-title>Functional imaging studies of emotion regulation: a synthetic review and evolving model of the cognitive control of emotion</article-title>. <source>Ann N Y Acad Sci</source> (<year>2012</year>) <volume>1251</volume>(<issue>1</issue>):<fpage>E1</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06751.x</pub-id><pub-id pub-id-type="pmid">23025352</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochsner</surname><given-names>KN</given-names></name><name><surname>Bunge</surname><given-names>SA</given-names></name><name><surname>Gross</surname><given-names>JJ</given-names></name><name><surname>Gabrieli</surname><given-names>JD</given-names></name></person-group>. <article-title>Rethinking feelings: an FMRI study of the cognitive regulation of emotion</article-title>. <source>J Cogn Neurosci</source> (<year>2002</year>) <volume>14</volume>(<issue>8</issue>):<fpage>1215</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1162/089892902760807212</pub-id><pub-id pub-id-type="pmid">12495527</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modinos</surname><given-names>G</given-names></name><name><surname>Ormel</surname><given-names>J</given-names></name><name><surname>Aleman</surname><given-names>A</given-names></name></person-group>. <article-title>Altered activation and functional connectivity of neural systems supporting cognitive control of emotion in psychosis proneness</article-title>. <source>Schizophr Res</source> (<year>2010</year>) <volume>118</volume>(<issue>1</issue>):<fpage>88</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2010.01.030</pub-id><pub-id pub-id-type="pmid">20188516</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anticevic</surname><given-names>A</given-names></name><name><surname>Repovs</surname><given-names>G</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name></person-group>. <article-title>Emotion effects on attention, amygdala activation, and functional connectivity in schizophrenia</article-title>. <source>Schizophr Bull</source> (<year>2012</year>) <volume>38</volume>(<issue>5</issue>):<fpage>967</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbq168</pub-id><pub-id pub-id-type="pmid">21415225</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eack</surname><given-names>SM</given-names></name><name><surname>Hogarty</surname><given-names>GE</given-names></name><name><surname>Greenwald</surname><given-names>DP</given-names></name><name><surname>Hogarty</surname><given-names>SS</given-names></name><name><surname>Keshavan</surname><given-names>MS</given-names></name></person-group>. <article-title>Cognitive enhancement therapy improves emotional intelligence in early course schizophrenia: preliminary effects</article-title>. <source>Schizophr Res</source> (<year>2007</year>) <volume>89</volume>(<issue>1</issue>):<fpage>308</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2006.08.018</pub-id><pub-id pub-id-type="pmid">17055227</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eack</surname><given-names>SM</given-names></name><name><surname>Greenwald</surname><given-names>DP</given-names></name><name><surname>Hogarty</surname><given-names>SS</given-names></name><name><surname>Keshavan</surname><given-names>MS</given-names></name></person-group>
<article-title>One-year durability of the effects of cognitive enhancement therapy on functional outcome in early schizophrenia</article-title>. <source>Schizophr Res</source> (<year>2010</year>) <volume>120</volume>(<issue>1</issue>):<fpage>210</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2010.03.042</pub-id><pub-id pub-id-type="pmid">20472402</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>DT</given-names></name><name><surname>Stanley</surname><given-names>JC</given-names></name></person-group>
<source>Experimental and Quasi-Experimental Designs for Research</source>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Wadsworth Publishing</publisher-name> (<year>1966</year>).</mixed-citation></ref></ref-list></back></article>